🔴 CLPT is trading 5.1% down today on regulatory uncertainty and weak revenue guidance

CLPT is trading 5.1% down at $17.76 in pre-market, pulling back after a recent rebound and ongoing volatility.

• The stock has faced pressure in 2026 stemming from weaker revenue guidance and regulatory uncertainty surrounding gene-therapy-related products.
• These factors continue to weigh on investor sentiment, contributing to cautious pre-market trading activity.
• The current decline follows a period of price swings as the market reassesses the company's growth trajectory and regulatory environment.